Sep 14, 2022 / 01:40PM GMT
Brian Peter Skorney - Robert W. Baird & Co. Incorporated, Research Division - Senior Research Analyst
Good morning, everyone. Thank you for joining us our next fireside chat. I'm really pleased to have with me the Chief Commercial Officer of Gilead Sciences, Johanna Mercier. Gilead is a name, I'm sure, everyone is familiar with. It's one of the bellwethers of the sector, a long-standing biotech company with an increasingly diversified portfolio of commercial and development offerings.
So Johanna, thanks so much for joining us today. Really glad to have you here. Maybe to just kind of kick things off, for people who aren't totally familiar with Gilead, you can just give them a very high-level overview of what the company is and is focused on as a biopharma.
Johanna Mercier - Gilead Sciences, Inc. - Chief Commercial Officer
Sure. So it's a softball, I like it. Thanks, Brian. It's great to be here. So thank you. Yes, I think Gilead really has been known as an HIV company. And I think you talked about it a little bit about the diversification. I think
Gilead Sciences Inc at Robert W Baird Global Healthcare Conference Transcript
Sep 14, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers